Show simple item record

dc.contributor.authorKlein, Matthew N
dc.contributor.authorWang, Elizabeth Wenqian
dc.contributor.authorZimand, Paul
dc.contributor.authorBeauchamp, Heather
dc.contributor.authorDonis, Caitlin
dc.contributor.authorWard, Matthew D
dc.contributor.authorMartinez-Hernandez, Aidaelis
dc.contributor.authorTabatabai, Ali
dc.contributor.authorBaddley, John W
dc.contributor.authorBloch, Evan M
dc.contributor.authorMullins, Kristin E
dc.contributor.authorFontaine, Magali J
dc.date.accessioned2021-04-28T15:10:14Z
dc.date.available2021-04-28T15:10:14Z
dc.date.issued2021-04-23
dc.identifier.urihttp://hdl.handle.net/10713/15533
dc.description.abstractAims: While the SARS-CoV-2 pandemic may be contained through vaccination, transfusion of convalescent plasma (CCP) from individuals who recovered from COVID-19 (CCP) is considered an alternative treatment. We investigate if CCP transfusion in patients with severe respiratory failure increases plasma titres of SARS-CoV-2 antibodies and improves clinical outcomes. Methods: Patients with COVID-19 (n=34) were consented for CCP transfusion and serial blood draws pretransfusion and post-transfusion. Plasma SARS-CoV-2 antireceptor binding domain (RBD) IgG and IgM titres were measured by ELISA serially, and compared with serial plasma titre levels from control patients (n=68). The primary outcome was survival at 30 days, and secondary outcomes were length of ventilator and/or extracorporeal membrane oxygenation (ECMO) support, length of stay (LOS) in the hospital and in the intensive care unit (ICU). Outcomes were compared with matched control patients (n=34). Kinetics of antibodies and clinical outcomes were compared using LOess regression and ORs, respectively. Results: Prior to CCP transfusion, 74% of patients were anti-RBD seropositive for IgG (median 1:3200), and 81% were anti-RBD IgM seropositive (median 1:320), while 16% were seronegative. The kinetics of antibody titres in CCP recipients were similar to controls. CCP recipients presented with similar survival, duration on ventilatory and/or ECMO support, as well as ICU and hospital LOS compared with controls. Conclusions: CCP transfusion did not increase the kinetics of SARS-CoV2 antibodies and did not result in improved clinical outcomes in patients with COVID-19 with severe respiratory failure, suggesting that CCP may not be indicated in this category of patients.en_US
dc.description.urihttps://doi.org/10.1136/jclinpath-2020-207356en_US
dc.description.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072701/en_US
dc.language.isoenen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.ispartofJournal of Clinical Pathologyen_US
dc.rights© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.en_US
dc.subjectCOVID-19en_US
dc.subjectantibodiesen_US
dc.subjectblood transfusionen_US
dc.titleKinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case-control studyen_US
dc.typeArticleen_US
dc.identifier.doi10.1136/jclinpath-2020-207356
dc.identifier.pmid33893156
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record